You are here

Approvals, Launches, and New Indications

Approval marks major step in precision medicine
Wholesale acquisition cost is $39,000 per year
Approval marks the fifth type of cancer for which the drug is indicated
Immunotherapy also treats Merkel cell carcinoma
Human monoclonal antibody demonstrates durable responses
Treatment reduces fractures and increases BMD compared with placebo
Accelerated approval based on mid-stage response rate